Kemwell Biopharma, a biologics contract development and manufacturing service provider, has signed a contract to manufacture and supply drug substance using its mammalian cell culture plant in India for Phase III clinical trials that will be conducted in the U.S. by its customer for a BLA filing.    Kemwell provided the customer with technology transfer, process optimization, scale-up, manufacturing of toxicology materials and cGMP manufacturing of drug substance clinical materials, and releas...